Acutaas Chemicals Q3 FY26 Results: Net Loss Widens to ₹123.12 Lakhs
Acutaas Chemicals Limited reported a standalone net loss of ₹123.12 lakhs for Q3 FY26, an increase from ₹29.60 lakhs in Q3 FY25. Consolidated net profit after tax rose to ₹36.38 lakhs from ₹47.65 lakhs year-on-year. Total income from operations for the quarter was ₹740.70 lakhs (standalone) and ₹1382.47 lakhs (consolidated).
While the standalone results show a deterioration, the consolidated results show a slight improvement in profit, making the overall impact medium.
The standalone net loss has widened significantly, indicating a negative financial performance for the quarter.
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) has announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company reported a standalone net loss after tax of ₹123.12 lakhs for the quarter ended December 31, 2025, compared to a net loss of ₹29.60 lakhs in the same period last year. The total income from operations for the quarter stood at ₹740.70 lakhs.
For the nine months ended December 31, 2025, the standalone net loss after tax was ₹1047.58 lakhs. The total income from operations for the nine-month period was ₹2342.31 lakhs.
The consolidated results for the quarter ended December 31, 2025, showed a net profit after tax of ₹36.38 lakhs, a significant increase from ₹47.65 lakhs in the corresponding quarter of the previous year. Total income from operations for the consolidated entity was ₹1382.47 lakhs.
For the nine months ended December 31, 2025, the consolidated net profit after tax was ₹118.12 lakhs, compared to ₹106.58 lakhs in the same period last year. The total consolidated income from operations was ₹3934.85 lakhs.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors on January 28, 2026. The full financial results are available on the websites of BSE, NSE, and the company's website.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.